{
  "version": "2.0",
  "description": "宝锐产品竞争力库：AI助手回答「产品优势/竞争力」的结构化底座。v2.0 由 4 份产品/市场资料重建（NGS产品册、病原检测培训、病原销售地图、产品推荐清单）。",
  "updated_at": "2026-09-09",
  "sources": [
    {
      "file": "NGS文库构建系列产品册-2025.pdf",
      "type": "产品册",
      "dir": "NGS建库/"
    },
    {
      "file": "病原检测市场与酶原料产品推广培训-2026.08.31.pdf",
      "type": "内部培训",
      "dir": "病原检测/"
    },
    {
      "file": "病原销售地图_20260831.xlsx",
      "type": "内部策略",
      "dir": "病原检测/"
    },
    {
      "file": "202607-产品推荐清单.xlsx",
      "type": "产品推荐清单",
      "dir": "根目录"
    },
    {
      "file": "康为世纪2026半年报竞品情报",
      "type": "竞品情报",
      "dir": "微信文章",
      "url": "https://mp.weixin.qq.com/s/Zu2fiZ3EXWPIuogT9FckKw"
    }
  ],
  "market_intel": {
    "tNGS": "10-15亿, 增速>30%, 增长极; 建库酶70%+依赖进口, 国产替代空间最大",
    "qPCR": "138.6亿基本盘, 增速~12%, 占分子诊断68%",
    "mNGS": "42.3亿, 增速28.6%, 疑难感染利器",
    "dPCR": "42.3亿, 增速28.7%, 高端补充",
    "等温扩增": "83.3亿POCT, 增速15.2%",
    "CRISPR": "12.6亿新兴, 增速28.6%",
    "竞争格局": "冻干酶胜率70%+(差异化利器); tNGS建库酶胜率50-60%(进口替代主力); CRISPR胜率60-70%(先发优势); qPCR Taq胜率60-70%",
    "核心打法": "qPCR入门建信任→tNGS提客单价→冻干/等温/CRISPR差异化→一体化建库mix省6个月研发周期",
    "康为世纪": "2026H1营收1.13亿(+29.73%)、亏损收窄、研发占比25.76%; 200余种分子检测原料酶+700余种核心产品, 6平台31核心技术(原料酶/核酸保存/提取纯化/qPCR/测序/基因合成); \"核心原料酶+试剂盒+检测服务\"一体化, 原料自供率写入成本竞争力; 83国内证+73海外备案, 新推一步法RT-qPCR全预混液(引物探针全预混仅加模板); 高端工具酶(高保真/测序工具/等温扩增)仍进口依赖, 国产立足中低端; 启示=分子诊断竞争越激烈掌握核心酶原料者成本弹性越大, 真正壁垒在酶性能指标与批次一致性"
  },
  "products": [
    {
      "id": "tngs-library-enzyme",
      "product_line": "tNGS/NGS 建库酶（一体化建库mix）",
      "category": "NGS 建库 · 增长极",
      "competitive_rating": 5,
      "position": "strong",
      "fabe": {
        "feature": "末端修复+加A+接头连接+文库扩增一体化建库mix（BR3D201通用 / BR3D301 Tn5一步法 / BR3N602酶切片段化）",
        "advantage": "客户无需自行配比多酶，研发周期6个月→2个月；Tn5建库1.8h（传统4h+）；起始量低至pg级",
        "benefit": "操作步骤减少60%，单测试成本降15%，多供应商管理成本归零",
        "evidence": "产品册：BR3D301 Tn5建库1.8h兼容Illumina；BR3D201通用建库100pg~1μg一步片段化+末修+加A；培训：建库酶70%+依赖进口(NEB/Thermo/IDT)"
      },
      "competitors": [
        "NEB",
        "Thermo",
        "Illumina",
        "诺唯赞",
        "恺佧"
      ],
      "skus": [
        "BR3D201",
        "BR3D301",
        "BR3N602",
        "BR3M105",
        "BR3P301",
        "BR3P103"
      ],
      "market": "tNGS 10-15亿增速>30%, 进口替代空间最大; 胜率50-60%",
      "pk_cases": [
        "weiyuan-mngs",
        "jinshi-mngs",
        "jinshi-tngs"
      ],
      "source": "NGS产品册 + 病原培训 + 销售地图",
      "status": "verified"
    },
    {
      "id": "super-multiplex-pcr",
      "product_line": "超多重PCR酶mix（tNGS前置扩增）",
      "category": "NGS 建库 · tNGS特有",
      "competitive_rating": 5,
      "position": "strong",
      "fabe": {
        "feature": "BR3M104（20-1000重）/ BR3M106（升级版NA级Taq，20-400+重）",
        "advantage": "扩增子GC 20%-80%全兼容；扩增均一性优于市面同类产品；兼容0.1ng低模板",
        "benefit": "tNGS低丰度病原不漏检；引物二聚体<3%，低丰度靶标检出率比进口高15%",
        "evidence": "产品册：BR3M106针对难扩增人外显子20重panel(GC27-80%)均一性优于N/Y公司同类；培训：超多重PCR酶是tNGS战略突破口、壁垒最高"
      },
      "competitors": [
        "KAPA",
        "NEB",
        "诺唯赞"
      ],
      "skus": [
        "BR3M104",
        "BR3M106",
        "BR3M101"
      ],
      "market": "tNGS增速>30%, 超多重PCR酶是tNGS与mNGS最大差异点",
      "pk_cases": [
        "jinshi-tngs"
      ],
      "source": "NGS产品册 + 病原培训",
      "status": "verified"
    },
    {
      "id": "freeze-dry-protectant",
      "product_line": "冻干酶体系（含冻干保护剂定制）",
      "category": "差异化 · 基层/POCT",
      "competitive_rating": 5,
      "position": "strong",
      "fabe": {
        "feature": "AS412-9 / AS212-9-T1 等冻干保护剂 + 全品类可冻干（Taq/逆转录/多重mix/qPCR/LAMP/CRISPR）",
        "advantage": "37℃加速30天活性保留≥95%；30秒复溶；开瓶稳定≥28天；常温运输省冷链成本30%",
        "benefit": "基层/疾控/POCT冷链痛点解决；帮客户打开基层市场",
        "evidence": "培训：37℃30天活性≥95%、30秒复溶、省30%冷链成本；销售地图：冻干酶胜率70%+(最高)；PK案例：迪安Q233液体转冻干一击即中"
      },
      "competitors": [
        "翌圣(仅通用型)",
        "诺唯赞"
      ],
      "skus": [
        "AS412-9",
        "AS212-9-T1",
        "AS212-000901",
        "消泡剂-3"
      ],
      "market": "胜率70%+; 差异化利器; 竞品未当独立品牌线打",
      "application_tips": [
        "客户试剂冻干后全样本复溶出现气泡、影响终端操作时，建议配套使用消泡剂-3，放入前处理系统（如释放剂）中，消泡效果明显且不影响性能。（来源：刘新元，2026-09-02）"
      ],
      "pk_cases": [
        "dian-q233-freeze-dry"
      ],
      "source": "病原培训 + 销售地图 + 产品推荐清单",
      "status": "verified"
    },
    {
      "id": "qpcr-enzyme",
      "product_line": "qPCR/RT-qPCR 酶（Taq/逆转录/多重mix/UNG）",
      "category": "分子诊断 · 基本盘",
      "competitive_rating": 4,
      "position": "strong",
      "fabe": {
        "feature": "热启动Taq酶(抗体/化学法)、M-MuLV逆转录酶、多重PCR mix、UNG+dUTP、高保真酶",
        "advantage": "批间CV≤5%(承诺≤10%)；粗样本(全血/痰液)耐受；交货1周(进口4-8周)；价格低30%",
        "benefit": "帮客户把试剂盒批间CV控在5%以内；断供风险归零",
        "evidence": "培训：批间CV≤10%承诺、粗样本耐受、一步法RT-qPCR；销售地图：qPCR Taq胜率60-70%，国产替代+稳定供应"
      },
      "competitors": [
        "Thermo",
        "Roche",
        "NEB",
        "诺唯赞",
        "翌圣",
        "博迈伦"
      ],
      "skus": [
        "MD2104系列",
        "M2181-4系列",
        "MD2091",
        "M2274系列"
      ],
      "market": "138.6亿基本盘, 占68%; 胜率60-70%",
      "pk_cases": [],
      "source": "病原培训 + 销售地图 + 产品推荐清单",
      "status": "verified"
    },
    {
      "id": "fast-direct-amplification",
      "product_line": "快速直扩/可冻干酶体系（FMD5104/FMD5084系列）",
      "category": "POCT · 快速直扩 · 差异化",
      "competitive_rating": 5,
      "position": "strong",
      "fabe": {
        "feature": "FMD5104-014429（超快速酶，血液/血清直扩）/ FMD5104-000829、000830（拭子样本）/ FMD5084-4（可冻干，耐抑制）",
        "advantage": "超快速直扩（变性1s/延伸3s级）；低浓度检出比诺唯赞QL227 cT提前约2个；支持冻干球/冻干粉；配套消泡剂-3解决冻干复溶气泡",
        "benefit": "帮客户实现20分钟以内超快速POCT；冻干全样本复溶无气泡，不影响终端操作",
        "evidence": "一线反馈（刘新元/宋学伟，2026-09）：014429登革热血清直扩cT比诺唯赞QL227提前约2；829/830适合拭子，014429适合血液直扩；5084-4委托冻干300T（南京英诺唯真）；消泡剂-3放释放剂中消泡明显且不损性能"
      },
      "competitors": [
        "诺唯赞 QL227（快速直扩·登革热血清）",
        "诺唯赞 Q225（可冻干版快速体系）"
      ],
      "skus": [
        "FMD5104-014429",
        "FMD5104-000829",
        "FMD5104-000830",
        "FMD5084-4",
        "消泡剂-3"
      ],
      "market": "POCT快速直扩, 超快速机型(雅睿20min)配套, 国产替代诺唯赞快速体系",
      "pk_cases": [
        "novizyme-ql227-dengue",
        "novizyme-q225-rapid-rt",
        "novizyme-q631-rna-premix"
      ],
      "source": "刘新元一线反馈 2026-09",
      "status": "pending_review"
    },
    {
      "id": "hybrid-capture",
      "product_line": "杂交捕获（HPV分型）",
      "category": "分子诊断 · 存量市场",
      "competitive_rating": 4,
      "position": "niche",
      "fabe": {
        "feature": "普通Taq酶 + 生物素标记dNTP（HPV分型主流方法）",
        "advantage": "对酶性能要求低于qPCR，核心是扩增产量和特异性；成本敏感",
        "benefit": "HPV试剂厂家成本可控",
        "evidence": "培训：HPV占杂交捕获试剂70%+，凯普/亚能主流；产品推荐清单：HPV MMCA用M3291/M2181-4"
      },
      "competitors": [
        "诺唯赞",
        "翌圣"
      ],
      "skus": [
        "M3291",
        "M2181-4"
      ],
      "market": "HPV杂交捕获约4.5亿, 存量市场",
      "pk_cases": [],
      "source": "病原培训 + 产品推荐清单",
      "status": "verified"
    },
    {
      "id": "human-depletion",
      "product_line": "人源去除酶方案（mNGS差异化）",
      "category": "mNGS 建库 · 差异化",
      "competitive_rating": 4,
      "position": "niche",
      "fabe": {
        "feature": "DNase I/盐激活核酸酶（皂苷兼容型）、S1核酸酶、MCN；超洁净车间生产（参照GMP，针对人源核酸特点做人员/着装/器具专用工艺控制SOP）",
        "advantage": "①生产端防污染：超洁净车间为RNase P/GapdH等管家基因内标的IVD企业提供防人源污染保障（竞品少有）；②性能端：血浆/肺泡灌洗液人源>95%，去宿主效率>95%且病原核酸损失<10%",
        "benefit": "病原reads占比从<5%提升到>15%，同样数据量病原reads多4倍，测序成本降40%",
        "evidence": "【生产端·已提供】参照GMP标准，针对人源核酸特点做人员数量/着装/器具专用工艺控制SOP，超洁净车间运行；【性能端·待补】去宿主效率/回收率/批次CV等定量benchmark（来源：刘新元口述，2026-09-01）"
      },
      "competitors": [
        "NEB",
        "Thermo"
      ],
      "skus": [],
      "market": "mNGS 42.3亿, 去宿主直接决定检出灵敏度",
      "pk_cases": [
        "weiyuan-mngs",
        "jinshi-mngs"
      ],
      "source": "病原培训",
      "status": "pending_review"
    },
    {
      "id": "ngs-library-kit",
      "product_line": "NGS 通用建库试剂盒（独立品牌线）",
      "category": "NGS 建库 · 竞争红海",
      "competitive_rating": 3,
      "position": "weak",
      "fabe": {
        "feature": "通用 NGS DNA/RNA 建库试剂盒",
        "advantage": "耗材走量最大但竞争最惨烈",
        "benefit": "（暂不占优，建议绑定国产测序仪做适配）",
        "evidence": "chat_history结论：翌圣Hieff NGS全套+临床级、诺唯赞全场景建库已与真迈测序仪形成生态闭环，通用建库盒拼不过规模与生态绑定"
      },
      "competitors": [
        "翌圣",
        "诺唯赞",
        "真迈"
      ],
      "skus": [],
      "market": "竞争红海, 需差异化",
      "pk_cases": [],
      "source": "chat_history 刘子研问答",
      "status": "pending_review"
    },
    {
      "id": "isothermal-bst",
      "product_line": "等温扩增 Bst 酶（LAMP/RPA）",
      "category": "POCT · 新兴",
      "competitive_rating": 4,
      "position": "opportunity",
      "fabe": {
        "feature": "Bst 3.0 HS DNA聚合酶（大片段链置换）、逆转录酶、重组酶/SSB",
        "advantage": "15-30分钟出结果，无需PCR仪，恒温37-65℃",
        "benefit": "POCT现场/基层/疾控应急场景刚需",
        "evidence": "培训：等温扩增83.3亿POCT增速15.2%，Bst是核心；产品推荐清单：LAMP染料法HW205-R02-064803(Bst3.0 HS)"
      },
      "competitors": [
        "NEB",
        "诺唯赞",
        "翌圣"
      ],
      "skus": [
        "HW205-R02-064803",
        "HW206-R02-068601",
        "E42",
        "E105"
      ],
      "market": "83.3亿POCT, 胜率40-50%, 冻干差异化",
      "pk_cases": [],
      "source": "病原培训 + 产品推荐清单",
      "status": "verified"
    },
    {
      "id": "crispr-cas",
      "product_line": "CRISPR 检测酶（Cas蛋白/T7酶）",
      "category": "新兴赛道",
      "competitive_rating": 4,
      "position": "opportunity",
      "fabe": {
        "feature": "Cas12a/Cas13a蛋白、T7 RNA聚合酶、RNase抑制剂、整体CRISPR检测mix",
        "advantage": "单分子级灵敏度、单碱基差异区分；T7转录效率≥1.2mg/mL；国产CRISPR原料稀缺",
        "benefit": "客户做CRISPR POCT/耐药快检/肿瘤早筛的新技术验证",
        "evidence": "培训：CRISPR 12.6亿增速28.6%，Cas/T7是核心，mRNA平台延伸；销售地图：CRISPR胜率60-70%先发优势"
      },
      "competitors": [
        "IDT",
        "NEB"
      ],
      "skus": [],
      "market": "12.6亿新兴, 胜率60-70%先发优势",
      "pk_cases": [],
      "source": "病原培训 + 销售地图",
      "status": "pending_review"
    },
    {
      "id": "dpcr-enzyme",
      "product_line": "dPCR 数字PCR专用酶",
      "category": "高端补充",
      "competitive_rating": 3,
      "position": "opportunity",
      "fabe": {
        "feature": "dPCR专用Taq酶、抗抑制mix、RT-dPCR酶、微滴兼容配方",
        "advantage": "抗微滴界面干扰、定制配方、价格优势",
        "benefit": "血流感染低载量绝对定量、病毒低载量、耐药突变",
        "evidence": "培训：dPCR 42.3亿增速28.7%，仪器被Bio-Rad/Thermo垄断但酶原料仍进口为主，国产替代空间大；销售地图：胜率40-50%国产填补"
      },
      "competitors": [
        "Bio-Rad",
        "Thermo"
      ],
      "skus": [],
      "market": "42.3亿, 国产填补, 胜率40-50%",
      "pk_cases": [],
      "source": "病原培训 + 销售地图",
      "status": "pending_review"
    }
  ],
  "pk_cases": [
    {
      "id": "dian-q233-freeze-dry",
      "product_line": "freeze-dry-protectant",
      "customer": "迪安诊断",
      "project": "呼吸道SNP病原检测RNA项目",
      "pk_competitor": "诺唯赞 Q233（液体配方）",
      "our_solution": [
        "FMD5104-074901 + AS212-9-T1 冻干保护剂",
        "FMD5084-000903 + AS412-9 冻干保护剂"
      ],
      "result": "一击即中，客户将Q233液体配方转冻干",
      "promotion_value": "「液体配方转冻干」标杆案例，面向冻干转型客户复制",
      "source": "chat_history 刘新元",
      "status": "verified"
    },
    {
      "id": "weiyuan-mngs",
      "product_line": "tngs-library-enzyme",
      "customer": "微远基因",
      "project": "呼吸道病原体mNGS（全球首款，2026-08-31获批，cPAS平台）",
      "pk_competitor": "进口建库酶（NEB/Thermo）",
      "our_solution": "phi29聚合酶（cPAS平台DNB制备核心，壁垒最高）+ 一体化建库mix + 去宿主酶 + RNA建库酶",
      "result": "切入策略：phi29战略突破口→建库mix粘性强→去宿主差异化→RNA延伸",
      "promotion_value": "phi29帮客户DNB均一性CV控8%以内、测序Q30提升3-5个百分点",
      "source": "病原培训 2.9案例一",
      "status": "verified"
    },
    {
      "id": "jinshi-mngs",
      "product_line": "tngs-library-enzyme",
      "customer": "金匙医学",
      "project": "血流感染mNGS（国内首款，2026-08-31获批，可逆末端终止法）",
      "pk_competitor": "NEB Ultra II FS",
      "our_solution": "pg级起始高保真建库mix + 血浆去宿主酶 + cfDNA专用连接酶",
      "result": "文库产量比进口高20%、扩增重复率低5个百分点、去宿主效率>95%",
      "promotion_value": "血流感染pg级起始专属方案，病原检出灵敏度提升1个数量级",
      "source": "病原培训 2.9案例二",
      "status": "verified"
    },
    {
      "id": "jinshi-tngs",
      "product_line": "super-multiplex-pcr",
      "customer": "金匙医学",
      "project": "新冠tNGS（国械注准20243401661，2024-09-02获批）",
      "pk_competitor": "KAPA/NEB 进口超多重PCR酶",
      "our_solution": "超多重PCR酶mix（50-500重）+ RT-PCR一步法 + 建库mix一体化",
      "result": "扩增子均一性CV≤25%、引物二聚体<3%、低丰度检出率比进口高15%",
      "promotion_value": "tNGS全链条一站式供应（逆转录+超多重PCR+建库mix），非单酶销售",
      "source": "病原培训 2.9案例三",
      "status": "verified"
    },
    {
      "id": "novizyme-ql227-dengue",
      "product_line": "fast-direct-amplification",
      "customer": "通用打法（具体客户待补充）",
      "project": "登革热病毒 快速直扩（血清样本）",
      "pk_competitor": "诺唯赞 QL227",
      "our_solution": "FMD5104-014429（低浓度检出 cT 值提前约2个）",
      "result": "014429 更适合血液样本直扩；FMD5104-000829/830 更适合拭子样本直扩",
      "promotion_value": "快速直扩+登革热病毒+血清样本场景，低浓度检出 cT 提前约2，替代诺唯赞QL227",
      "source": "chat_history 刘新元",
      "status": "verified"
    },
    {
      "id": "novizyme-q225-rapid-rt",
      "product_line": "fast-direct-amplification",
      "customer": "通用打法（雅睿超快速机型客户）",
      "project": "呼吸道快速体系（甲流/乙流/合胞，20分钟以内）",
      "pk_competitor": "诺唯赞 Q225（快速体系酶，有可冻干版本）",
      "our_solution": "FMD5104-014429 / FMD5104-000829、830",
      "result": "Q225在雅睿超快速机型（变性1s/延伸3s左右，超声释放）测甲流靶标相对扩增性能偏弱；我方同场景可推上述货号对标",
      "promotion_value": "快速直扩（20分钟内）呼吸道项目，Q225甲流靶标偏弱是切入机会",
      "source": "chat_history 刘新元（江苏区域反馈）",
      "status": "pending_review"
    },
    {
      "id": "novizyme-q631-rna-premix",
      "product_line": "fast-direct-amplification",
      "customer": "通用打法（具体客户待补充）",
      "project": "全预混RNA快速体系（直扩裂解）",
      "pk_competitor": "诺唯赞 Q631（全预混RNA快速体系，当前主推）",
      "our_solution": "FMD5104-000829-DB",
      "result": "直扩裂解快速性能，我方000829-DB可完全匹配甚至更好",
      "promotion_value": "诺唯赞Q631主推全预混RNA快速体系，直扩裂解场景我方000829-DB可对标替代",
      "source": "chat_history 刘新元（江苏区域反馈）",
      "status": "pending_review"
    }
  ],
  "application_tips": [
    {
      "id": "antifoam-3-fd-rehydration",
      "topic": "冻干试剂全样本复溶气泡问题",
      "scenario": "客户用我方试剂冻干后，全样本复溶出现气泡，影响终端操作使用",
      "suggestion": "建议客户使用消泡剂-3 放在前处理系统（如释放剂中），消泡效果明显且不影响性能",
      "source": "chat_history 刘新元",
      "status": "verified"
    },
    {
      "id": "glycerol-content-m2181-premix",
      "topic": "M2181-4-095201（2×FastAmpli Premix-UNG IV，Probe qPCR）甘油含量",
      "scenario": "客户询问该款非可冻干类mix是否含甘油、浓度多少（甘油浓度直接影响冻干可行性，非可冻干类不可直接冻干）",
      "suggestion": "我司非可冻干类mix采用的Taq酶储液含约50%甘油；按2×使用，最终配制完成后甘油浓度约2-3%",
      "source": "刘新元一线确认 2026-09",
      "status": "verified"
    }
  ]
}